A hemophagocytic lymphohistiocytosis case with newly defined UNC13D (C.175G>C; p.Ala59Pro) mutation and a rare complication [PDF]
, 2015 Hemophagocytic lymphohistiocytosis (HLH) represents a severe hyperinflammatory condition with cardinal symptoms of prolonged fever, cytopenias, hepatosplenomegaly, and hemophagocytosis by activated, morphologically benign macrophages with impaired ...
Akpınar, Funda Özgürler +7 more
core +2 more sources
SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1 [PDF]
, 2013 BACKGROUND We have previously identified kinase suppressor of ras-1 (KSR1) as a potential regulatory gene in breast cancer. KSR1, originally described as a novel protein kinase, has a role in activation of mitogen-activated protein kinases.
A Filipovic +47 more
core +2 more sources
Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. [PDF]
, 2016 Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive immune activation that mimics and occurs with other systemic diseases. A 35-year-old female presented with signs of viral illness at 13 weeks of pregnancy and progressed to acute liver ...
Decker, Kerry A +5 more
core +1 more source
Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1:a novel anticancer small-molecule [PDF]
, 2015 Restoration of the p53 pathway, namely by reactivation of mutant (mut) p53, represents a valuable anticancer strategy. Herein, we report the identification of the enantiopure tryptophanol-derived oxazoloisoindolinone SLMP53-1 as a novel reactivator of ...
Bessa, Cláudia +15 more
core +3 more sources
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]
, 2020 Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David +5 more
core +2 more sources
Cancer Medicine, 2023 Background To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). Methods Retrospective analysis was performed on patients with advanced TNENs confirmed
Yelan Guan +8 more
doaj +1 more source
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide [PDF]
British Journal of Cancer, 1997 Etoposide phosphate is a water-soluble prodrug of etoposide. The plasma pharmacokinetics of etoposide following oral administration of etoposide phosphate or oral etoposide were compared. Seventeen patients with solid tumours were enrolled to receive oral etoposide phosphate 125 mg m(-2) on days 1-5 every 3 weeks, with escalation to 175 mg m(-2) from ...
deJong, RS +9 more
openaire +3 more sources
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]
, 2017 BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David +4 more
core +1 more source
Pharmaceutics, 2020 Small cell lung carcinoma (SCLC) is a highly aggressive form of malignancy with rapid recurrence and poor prognosis. The dual peptide-modified nanoparticles (NPs) for improving chemotherapy against drug-resistant small cell lung carcinoma cells has been ...
Hsin-Lin Huang, Wen Jen Lin
doaj +1 more source
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study [PDF]
, 2018 Purpose In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs).
AnnaLynn M. Williams +20 more
core +1 more source